Iranian Journal of Allergy, Asthma and Immunology 2017. 16(5):418-424.

Macrophages from Behcet's Disease Patients Express Decreased Level of Aryl Hydrocarbon Receptor (AHR) mRNA
Mohammad Taghi Palizgir, Maryam Akhtari, Mahdi Mahmoudi, Shayan Mostafaei, Alireza Rezaeimanesh, Massoomeh Akhlaghi, Farhad Shahram

Abstract


Aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor, connecting environmental stimulators with the immune system. M1 macrophages are a part of immune system that contribute to the inflammatory events in the pathogenesis of Behcet's disease (BD). The effect of AHR on the macrophages in BD patients is still unclear. In this study, we investigated the mRNA expression of AHR in the monocyte-derived and M1 macrophages in active BD patients in comparison to healthy controls. Isolated monocytes from 10 healthy controls and 10 active BD patients were differentiated to macrophages by macrophage-colony stimulating factor (M-CSF) for 7 days. Cells were then polarized to M1 macrophages by lipopolysaccharide (LPS) and interferon-γ (IFNγ) for 24h. Monocyte purity and macrophage markers expression were analyzed by flow cytometry. Analysis of AHR mRNA expression was performed by SYBR Green real-time PCR. Our results showed that AHR expression is significantly down-regulated in M1 macrophages compare to monocyte-derived macrophages. It was shown that both monocyte-derived macrophages and M1 macrophages from BD patients significantly express lower level of AHR mRNA compared to healthy individuals. Our results demonstrate an anti-inflammatory role for AHR in macrophages, which suggest that decreased AHR expression is associated with pro-inflammatory M1 macrophage and BD susceptibility.


Keywords


Aryl hydrocarbon receptor; Behcet's disease; Gene expression

Full Text:

PDF

References


style='font-size:12.0pt;mso-bidi-font-family:"B Yagut";color:#231F20'>

style='mso-element:field-begin'>

color:#231F20'> ADDIN EN.REFLIST

style='font-size:12.0pt;mso-bidi-font-family:"B Yagut";color:#231F20'>

style='mso-element:field-separator'>1. Mazzoccoli G, Matarangolo A, Rubino R, Inglese M, De Cata A. Behcet syndrome: from pathogenesis to novel therapies. Clin Exp Med 2016; 16(1):1-12.
2. Mat MC, Sevim A, Fresko I, Tuzun Y. Behcet's disease as a systemic disease. Clin Dermatol 2014; 32(3):435-42.
3. Davatchi F, Jamshidi AR, Banihashemi AT, Gholami J, Forouzanfar MH, Akhlaghi M, et al. WHO-ILAR COPCORD Study (Stage 1, Urban Study) in Iran. J Rheumatol 2008; 35(7):1384.
4. Palizgir M, Mahmoudi M, Qorbani M, Djalalinia S, Mostafaei S, Shahram F. Prevalence and Clinical Investigation of the Behcet’s Disease in Middle East and North Africa: A Systematic Review and Meta-Analysis. Iran Red Crescent Med J.In press(In press):e43313.
5. Laria A, Lurati A, Marrazza M, Mazzocchi D, Re KA, Scarpellini M. The macrophages in rheumatic diseases. J Inflamm Res 2016; 9:1-11.
6. Gul A. Pathogenesis of Behcet's disease: autoinflammatory features and beyond. Semin Immunopathol 2015; 37(4):413-8.
7. Mohammadi-Bardbori A, Bengtsson J, Rannug U, Rannug A, Wincent E. Quercetin, resveratrol, and curcumin are indirect activators of the aryl hydrocarbon receptor (AHR). Chem Res Toxicol 2012; 25(9):1878-84.
8. Stockinger B, Di Meglio P, Gialitakis M, Duarte JH. The aryl hydrocarbon receptor: multitasking in the immune system. Annu Rev Immunol 2014; 32:403-32.
9. Nguyen NT, Nakahama T, Nguyen CH, Tran TT, Le VS, Chu HH, et al. Aryl hydrocarbon receptor antagonism and its role in rheumatoid arthritis. J Exp Pharmacol 2015; 7:29-35.
10. Busbee PB, Rouse M, Nagarkatti M, Nagarkatti PS. Use of natural AhR ligands as potential therapeutic modalities against inflammatory disorders. Nutr Rev 2013; 71(6):353-69.
11. Nguyen NT, Hanieh H, Nakahama T, Kishimoto T. The roles of aryl hydrocarbon receptor in immune responses. Int Immunol 2013; 25(6):335-43.
12. Kerkvliet NI, Steppan LB, Vorachek W, Oda S, Farrer D, Wong CP, et al. Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodes. Immunotherapy 2009; 1(4):539-47.
13. Marshall NB, Vorachek WR, Steppan LB, Mourich DV, Kerkvliet NI. Functional characterization and gene expression analysis of CD4+ CD25+ regulatory T cells generated in mice treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Immunol 2008; 181(4):2382-91.
14. Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008; 453(7191):65-71.
15. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet 1990; 335(8697):1078-80.
16. Rezaiemanesh A, Mahmoudi M, Amirzargar AA, Vojdanian M, Jamshidi AR, Nicknam MH. Ankylosing spondylitis M-CSF-derived macrophages are undergoing unfolded protein response (UPR) and express higher levels of interleukin-23. Mod Rheumatol 2016; 15:1-6.
17. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3(6):1101-8.
18. Dunster JL. The macrophage and its role in inflammation and tissue repair: mathematical and systems biology approaches. Wiley Interdiscip Rev Syst Biol Med 2016; 8(1):87-99.
19. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 2014; 6:13.
20. Jou IM, Lin CF, Tsai KJ, Wei SJ. Macrophage-mediated inflammatory disorders. Mediators Inflamm 2013;2013:316482.
21. Gholijani N, Ataollahi MR, Samiei A, Aflaki E, Shenavandeh S, Kamali-Sarvestani E. An elevated pro-inflammatory cytokines profile in Behcet's disease: A multiplex analysis. Immunol Lett 2016; 186:46-51.
22. Misumi M, Hagiwara E, Takeno M, Takeda Y, Inoue Y, Tsuji T, et al. Cytokine production profile in patients with Behcet's disease treated with infliximab. Cytokine 2003; 24(5):210-8.
23. Alpsoy E, Kodelja V, Goerdt S, Orfanos CE, Zouboulis Ch C. Serum of patients with Behcet's disease induces classical (pro-inflammatory) activation of human macrophages in vitro. Dermatology 2003; 206(3):225-32.
24. Zhu C, Xie Q, Zhao B. The role of AhR in autoimmune regulation and its potential as a therapeutic target against CD4 T cell mediated inflammatory disorder. Int J Mol Sci 2014; 15(6):10116-35.
25. Climaco-Arvizu S, Dominguez-Acosta O, Cabanas-Cortes MA, Rodriguez-Sosa M, Gonzalez FJ, Vega L, et al. Aryl hydrocarbon receptor influences nitric oxide and arginine production and alters M1/M2 macrophage polarization. Life Sci 2016; 155:76-84.
26. Kimura A, Naka T, Nakahama T, Chinen I, Masuda K, Nohara K, et al. Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses. J Exp Med 2009; 206(9):2027-35.
27. Sekine H, Mimura J, Oshima M, Okawa H, Kanno J, Igarashi K, et al. Hypersensitivity of aryl hydrocarbon receptor-deficient mice to lipopolysaccharide-induced septic shock. Mol Cell Biol 2009; 29(24):6391-400.
28. Wang C, Ye Z, Kijlstra A, Zhou Y, Yang P. Decreased expression of the aryl hydrocarbon receptor in ocular Behcet's disease. Mediators Inflamm 2014; 2014:195094.
29. Harel-Meir M, Sherer Y, Shoenfeld Y. Tobacco smoking and autoimmune rheumatic diseases. Nat Clin Pract Rheumatol 2007; 3(12):707-15.
30. Klareskog L, Padyukov L, Alfredsson L. Smoking as a trigger for inflammatory rheumatic diseases. Curr Opin Rheumatol 2007; 19(1):49-54.
31. Shamsian E, Azarian M, Akhlaghi M, Samaei M, Jamshidi AR, Assar S, et al. PADI4 Polymorphisms in Iranian Patients with Rheumatoid Arthritis. Acta Reumatol Port 2016; 41(4):338-43.
32. Fallahi S, Jamshidi AR, Gharibdoost F, Mahmoudi M, Ahmadzadeh N, Nicknam MH. The correlation between pack-years of smoking and disease activity, quality of life, spinal mobility, and sacroiliitis grading in patients with ankylosing spondylitis. Turk J Rheumatol 2013; 28(3):181-8.
33. Denison MS, Phelan D, Winter GM, Ziccardi MH. Carbaryl, a carbamate insecticide, is a ligand for the hepatic Ah (dioxin) receptor. Toxicol Appl Pharmacol 1998; 152(2):406-14.
34. Baglole CJ, Maggirwar SB, Gasiewicz TA, Thatcher TH, Phipps RP, Sime PJ. The aryl hydrocarbon receptor attenuates tobacco smoke-induced cyclooxygenase-2 and prostaglandin production in lung fibroblasts through regulation of the NF-kappaB family member RelB. J Biol Chem 2008; 283(43):28944-57.
35. Soy M, Erken E, Konca K, Ozbek S. Smoking and Behcet's disease. Clin Rheumatol 2000; 19(6):508-9.


Refbacks

  • There are currently no refbacks.


Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.